JP Morgan Maintains Overweight on Ascendis Pharma, Lowers Price Target to $174
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma (NASDAQ:ASND) but lowers the price target from $180 to $174.
October 23, 2024 | 11:50 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan's analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma but reduces the price target from $180 to $174, indicating a slightly less optimistic outlook.
The Overweight rating suggests continued confidence in Ascendis Pharma's potential, but the lowered price target reflects a slightly reduced expectation of its stock performance. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100